SCHEMBL15758317

SCHEMBL15758317

COc1ccc(CC(=O)Nc2ccc(Cl)c(Cl)c2)c(OC)c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.54
MEN1 O00255 5/20 0.54
TSHR P16473 1/20 0.54
MAPT P10636 3/20 0.53
POLB P06746 1/20 0.53
CYP3A4 P08684 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 1/20 0.51
HTR2A P28223 1/20 0.50
SLC6A4 P31645 1/20 0.50
KCNH2 Q12809 1/20 0.50
TP53 P04637 1/20 0.50
NPC1 O15118 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
APLNR P35414 1/20 0.48
P2RX4 Q99571 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19427487 0.87 MEN1 (0.62) KMT2AMEN1TSHRMAPTL3MBTL1
SCHEMBL15758638 0.82 SMN1; SMN2 (0.66) KMT2AMEN1MAPTPOLBCYP3A4
SCHEMBL3707448 0.81 QPCT (0.62) KMT2AMEN1MAPTALDH1A1HTR2A
SCHEMBL19427445 0.79 ALDH1A1 (0.75) KMT2AMEN1MAPTL3MBTL1ALDH1A1
SCHEMBL19427481 0.78 KMT2A (0.68) KMT2AMEN1TSHRMAPTPOLB
SCHEMBL15758031 0.77 EPHX2 (0.70) KMT2AMEN1MAPTALDH1A1TP53
SCHEMBL4362583 0.77 MEN1 (0.64) KMT2AMEN1TSHRPOLBALDH1A1
SCHEMBL19427517 0.76 HSD17B10 (0.60) KMT2AMEN1TSHRPOLBALDH1A1
SCHEMBL26090723 0.76 MEN1 (0.50) KMT2AMEN1TSHRMAPTALDH1A1
SCHEMBL26090714 0.76 MEN1 (0.50) KMT2AMEN1TSHRMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10912761-B2 Methods and compositions involving RAD51 inhibitors THE UNIVERSITY OF CHICAGO (US) 2021-02-09 US disclosed
US-20150306069-A1 METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS THE UNIVERSITY OF CHICAGO (US) 2015-10-29 US disclosed
WO-2014085545-A1 METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS THE UNIVERSITY OF CHICAGO (US) 2014-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10912761-B2 Methods and compositions involving RAD51 inhibitors RAD51, MRE11, RAD50 KMT2A 1387/4885MEN1 2019/4885TSHR 4391/4885
US-20150306069-A1 METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS RAD51, MRE11, RAD50 KMT2A 1387/4885MEN1 2019/4885TSHR 4391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.